Clinical trials · Colorado
Locally Advanced or Metastatic Solid Tumors clinical trials in Colorado
We’re tracking 220 recruiting locally advanced or metastatic solid tumors studies with a site in Colorado — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Colorado
- NCT06632977RecruitingPhase 2
Matching targeted treatments to your prostate cancer's genetics
This trial is testing whether matching your cancer's specific genetic changes to a targeted treatment can help control metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. You may receive a drug, a radioactive treatment, or a combination based on your tumor's molecular profile.
Colorado Springs, ColoradoAges 18 years+ - NCT06885034RecruitingPhase 1/Phase 2
Testing a New Drug for Advanced Colon, Rectal, or Pancreatic Cancer
This study tests an experimental drug, alone or combined with other treatments, for advanced colon, rectal, or pancreatic cancer that hasn't responded to standard options or cannot be removed by surgery. The goal is to see if it is safe and if it helps shrink or slow the cancer.
Aurora, ColoradoAges 18 years+ - NCT05011383RecruitingPhase 2
High dose testosterone for prostate cancer with ATM, CDK12, or CHEK2 changes
This trial is testing whether high doses of testosterone can help treat advanced prostate cancer in men who have a specific genetic change (ATM, CDK12, or CHEK2). It is for patients whose cancer has stopped responding to current hormone therapies.
Aurora, ColoradoAges 18 years+ - NCT07227298RecruitingPhase 1/Phase 2
Study of new drug combo for advanced lung cancer
This study tests a new combination of cancer drugs (PF-08634404 with other anticancer agents) for people with advanced non-small cell lung cancer who have not yet received any treatment for their advanced disease. It aims to see if this combination can shrink tumors or slow cancer growth.
Denver, ColoradoAges 18 years+ - NCT05253651RecruitingPhase 3
Tucatinib plus trastuzumab with chemo for HER2+ metastatic colon cancer
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
Aurora, ColoradoAges 18 years+ - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Boulder, ColoradoAges 18 years+ - NCT06788990RecruitingPhase 2/Phase 3
Study of ficerafusp alfa with pembrolizumab for advanced head and neck cancer
This study tests a new drug called ficerafusp alfa (BCA101) combined with the immunotherapy pembrolizumab for people with advanced head and neck cancer that has not been treated before. The goal is to see if adding ficerafusp alfa helps shrink tumors better than pembrolizumab alone.
Aurora, ColoradoAges 18 years+ - NCT06948448RecruitingPhase 2
New treatment for advanced colorectal cancer with PD-L1 biomarker
This trial tests a new drug (ONO-4578) combined with standard chemotherapy and immunotherapy for people with advanced colorectal cancer that has not been treated before and has a specific marker called PD-L1. The goal is to see if this combination works better than the usual treatment.
Lone Tree, ColoradoAges 18 years+ - NCT03016819RecruitingPhase 3
Test drugs anlotinib and catequentinib for advanced sarcoma
This Phase 3 study tests two anti-cancer medicines (anlotinib and catequentinib) for people with certain advanced soft-tissue sarcomas, including alveolar soft part sarcoma, synovial sarcoma, and leiomyosarcoma. It is designed for tumors that cannot be removed and that have either grown despite treatment or no longer respond to standard options.
Aurora, ColoradoAges 18 years+ - NCT04038502RecruitingPhase 2
Testing carboplatin or olaparib for gene-linked prostate cancer
This Phase 2 study tests whether carboplatin or olaparib can help people with prostate cancer that has certain DNA repair gene changes. It’s designed for advanced (metastatic) prostate cancer that is growing despite standard hormone-blocking treatment.
Aurora, ColoradoAges 18 years+ - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Denver, ColoradoAges 1–21 - NCT05642572RecruitingPhase 2
Test drug combinations for EGFR- and MET-changed lung cancer
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
Colorado Springs, ColoradoAges 18 years+ - NCT05969496RecruitingPhase 2
Pembrolizumab plus axitinib before kidney surgery for RCC with IVC tumor
This Phase 2 trial tests whether pembrolizumab plus axitinib can shrink kidney cancer before surgery, when there is tumor growth into the inferior vena cava (IVC). It may help make the operation easier and improve chances of long-term control.
Highlands Ranch, ColoradoAges 18 years+ - NCT06031688RecruitingPhase 2
Targeted treatment for lung cancer with a MET gene change
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
Fort Collins, ColoradoAges 18 minutes+ - NCT06070012RecruitingPhase 2
Tebentafusp for untreated metastatic uveal melanoma
This trial tests a new drug called tebentafusp for people with uveal melanoma that has spread to other parts of the body and who have not yet received any treatment for the metastatic disease. It requires a specific genetic marker (HLA-A*0201) and focuses on whether the drug can shrink or slow the growth of tumors.
Aurora, ColoradoAges 18 years+ - NCT06116682RecruitingPhase 2
Targeted treatment for MET-positive advanced lung cancer
This trial tests a targeted therapy for people with advanced non-small cell lung cancer whose tumors have extra copies of the MET gene. It's for those whose cancer has progressed after at least one prior treatment.
Fort Collins, ColoradoAges 18 years+ - NCT06282575RecruitingPhase 3
Zanidatamab plus chemo for advanced HER2-positive bile duct cancer
This phase 3 trial tests whether adding zanidatamab (a targeted antibody) to standard chemotherapy can improve outcomes for advanced HER2-positive biliary tract cancer. If you have this type of cancer that has spread or can't be removed, and you've had little or no prior treatment, this study might be an option.
Lone Tree, ColoradoAges 18 years+ - NCT06422143RecruitingPhase 3
Keytruda with or without Sac-TMT for advanced squamous lung cancer
This trial tests the combination of pembrolizumab (Keytruda) with or without a new drug, sacituzumab tirumotecan (Sac-TMT), as initial treatment for advanced squamous non-small cell lung cancer. It aims to see if adding Sac-TMT after initial treatment helps keep cancer under control longer.
Golden, ColoradoAges 18 years+ - NCT05482893RecruitingPhase 1/Phase 2
Spevatamig for advanced stomach, pancreas, or bile duct cancer
This trial tests a new drug called Spevatamig (PT886), alone or with different chemotherapy and/or immunotherapy combinations, for people with certain advanced stomach, pancreatic, or bile duct cancers. The goal is to see if it shrinks tumors and is safe.
Denver, ColoradoAges 18 years+ - NCT06663319RecruitingPhase 1
Study of JNJ-89402638 for metastatic colorectal and gastric cancers
This trial tests a new drug, JNJ-89402638, alone or with other treatments for people with metastatic colorectal or gastric cancer that has progressed after standard therapies. It aims to find safe and effective doses and combinations.
Aurora, ColoradoAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Littleton, ColoradoAges 18 years+ - NCT06119581RecruitingPhase 3
Oloromosib with Immunotherapy as First Treatment for KRAS G12C Lung Cancer
This trial tests a new targeted pill (olomorasib) combined with immunotherapy (pembrolizumab) and possibly chemotherapy for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and has not been treated before.
Lone Tree, ColoradoAges 18 years+ - NCT06922591RecruitingPhase 1/Phase 2
TNG462 for pancreatic and lung cancer with MTAP loss
This trial tests a new drug called TNG462, alone or combined with other drugs, for people with advanced pancreatic or non-small cell lung cancer whose tumors have a specific genetic change (loss of MTAP and a RAS mutation). It aims to see if TNG462 is safe and works better than current treatments.
Denver, ColoradoAges 18 years+ - NCT06966453RecruitingPhase 1/Phase 2
Study of disitamab vedotin for HER2-positive advanced breast cancer
This study tests a new drug called disitamab vedotin for people with advanced breast cancer that has a certain amount of HER2 protein. Depending on your HER2 and hormone receptor status, you may be eligible for one of three groups, each with different prior treatment requirements.
Denver, ColoradoAges 18 years+
Locally Advanced or Metastatic Solid Tumors trials by city in Colorado
Where these studies are running in Colorado
Institutions with a site for the recruiting locally advanced or metastatic solid tumors studies listed above.
- Rocky Mountain Cancer Centers · 7 studies
- Advanced Neurology of Colorado · 4 studies
- Poudre Valley Hospital · 4 studies
- UCHealth Greeley Hospital · 4 studies
- UCHealth Medical Center of the Rockies · 4 studies
- UCHealth Memorial Hospital Central · 4 studies
- UCHealth Memorial Hospital North · 4 studies
- UCHealth University of Colorado Hospital · 4 studies
What taking part in a locally advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Locally Advanced or Metastatic Solid Tumors trials in other states
Common questions
- Are there locally advanced or metastatic solid tumors clinical trials in Colorado?
- Yes. We're currently tracking 220 recruiting locally advanced or metastatic solid tumors studies with a site in Colorado, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a locally advanced or metastatic solid tumors study in Colorado?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Colorado to take part?
- Not necessarily. These studies have a site in Colorado, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New locally advanced or metastatic solid tumors studies open in Colorado regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.